Erschienen in:
01.04.2008 | Adis Drug Profile
Dalbavancin
A Viewpoint by Eric S. Schweiger
verfasst von:
Eric S. Schweiger
Erschienen in:
Drugs
|
Ausgabe 5/2008
Einloggen, um Zugang zu erhalten
Excerpt
As the rates of antibiotic resistant bacteria continue to rise, the need for additional antibacterials to add to our armamentarium grows. Dalbavancin is a new medication under review by the US FDA for the treatment of complicated skin and skin structure infections. Dalbavancin, belonging to the same class as vancomycin, is a semi-synthetic glycoprotein that acts by inhibiting bacterial cell wall synthesis. …